Jasmin Hundal

Dr. Jasmin Hundal


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2025 in AI in Precision Oncology
Verified
Journal Article
Closed access
JHJasmin Hundal
Jasmin Hundal
MJMolly Jain
Molly Jain
JMJoseph McCollom
Joseph McCollom
Introduction: Ambient artificial intelligence (AAI) is increasingly being integrated into clinical workflows to address the documentation burden contributing to clinician burnout. AAI systems use automatic speech recognition and natural language processing to capture real-time clinician–patient dialogue and generate structured documentation within the electronic health record. Methods: This review examines AAI’s technical foundations, clinical applications, and implementation considerations in oncology practice. We describe how current AAI tools extract, classify, and populate relevant clinical content, such as the history of present illness, physical examination findings, and assessment and plan, while adhering to established US coding standards (e.g., International Classification of Diseases [ICD-10]). Key commercially available systems, including Nuance DAX Copilot, Ambience Healthcare, Tali AI, Athelas Scribe, and Nabla, are compared in terms of functionality, integration capabilities, and reported outcomes. Practical guidance is provided on clinician onboarding, device setup, customization, and patient consent. Results: Early data suggest AAI implementation can reduce after-hours documentation, improve note quality, and enhance coding accuracy. However, barriers such as transcription errors, hallucinations, and workflow disruptions must be proactively addressed. To ensure safe and effective integration, oncology practices adopting AAI should prioritize targeted training, documentation oversight, and user feedback. Conclusion: Although preliminary findings are promising, further prospective, multi-institutional studies are warranted to evaluate the impact of AAI on clinical efficiency, data quality, and patient outcomes in oncology. This review provides a foundational framework for researchers, clinicians, and health systems seeking to implement AAI in precision oncology documentation.

12 July 2025 in American Journal of Lifestyle Medicine
Verified
Journal Article
Closed access
JHJasmin Hundal
Jasmin Hundal
SPSupriya Peshin
Supriya Peshin
RGRahat Ghazanfar
Rahat Ghazanfar
SHSandi Hayes
Sandi Hayes
SMSami Mansfield
Sami Mansfield
ACAmy Comander
Amy Comander
Cardiovascular disease and cancer are the leading causes of mortality in developed countries. Advances in screening and treatment have led to a growing population of cancer survivors who require long-term supportive care. Many experience persistent health challenges, including fatigue, functional decline, and cardiometabolic comorbidities. Lifestyle medicine, which includes nutrition, physical activity, stress management, sleep, social connections, and risk reduction, provides a structured approach to optimizing survivorship outcomes.This narrative review examines the role of Lifestyle Medicine in oncology and highlights global implementation models. Programs analyzed include the Mass General Cancer Center’s Lifestyle Medicine Clinic, the Clinical Oncology Society of Australia’s exercise oncology framework, the Cleveland Clinic Abu Dhabi’s Lifestyle Medicine Oncology Program, and Kansas City’s community-based Cancer Wellness for Life initiative. Across diverse clinical settings, structured lifestyle interventions have been associated with improved treatment tolerance, quality of life, and the potential to reduce cardiometabolic risk factors. Hospital-based programs integrate multidisciplinary support, while community-driven initiatives expand access to lifestyle interventions. Despite strong evidence supporting these approaches, barriers to widespread adoption include gaps in clinician training, limited institutional support, and disparities in patient access. Global models show the feasibility and advantages of integrating Lifestyle Medicine into survivorship care. Increasing access, overcoming implementation challenges, and using technology can improve survivorship outcomes. Including Lifestyle Medicine in standard oncology care can improve long-term health and encourage survivors to manage their well-being actively.

13 June 2022 in Cureus
Verified
Journal Article
Open access
JHJasmin Hundal
Jasmin Hundal
NLNerea Lopetegui-Lia
Nerea Lopetegui-Lia
JVJames Vredenburgh
James Vredenburgh
Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Many studies show lung cancer is a histologically and molecularly heterogeneous group, even within the same histological subtype. Liquid biopsies are a new tool that can identify targetable genomic mutations and impact management. JAK2 p.V617F is a mutation commonly found in myeloproliferative neoplasms but rarely identified in non-small cell lung cancer (NSCLCs). The significance of Janus Kinase (JAK2) mutation in lung cancer is not clearly understood. However, it is thought that it may have a role in treating solid tumors, such as lung cancer. We present two cases of patients diagnosed with NSCLC who were discovered to have JAK2 V617F mutation on liquid biopsy.

4 May 2021 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
JHJasmin Hundal
Jasmin Hundal
NLNerea Lopetegui-Lia
Nerea Lopetegui-Lia
WRWilliam Rabitaille
William Rabitaille
Background: Primary fallopian tube carcinoma (PFTC) is a rare gynecological malignancy though its prevalence may be underestimated given that most ‘ovarian’ serous cancers originate in the fallopian tube. Its diagnosis is challenging due to its vague signs and symptoms on presentation and it is frequently under-diagnosed pre-operatively. Case Presentation: We present a case of a pre-menopausal woman who presented with vaginal bleeding. Her laboratory testing and physical examination were grossly unremarkable. Gynecologic ultrasound demonstrated multiple uterine fibroids and a double layer endometrium measuring 4.5 mm. More importantly, the left ovary was seen with a complex cyst with mildly echogenic fluid and a solid excerscence. These findings were suspicious for malignancy. The clinical and radiological findings with elevated CA-125 were consistent with a malignant process. Patient subsequently underwent a diagnostic laparoscopy, which required conversion to exploratory laparotomy, supracervical hysterectomy, bilateral salpingo-oophorectomy, right ureteral lysis, right para-aortic and right pelvic lymph node debulking and omentectomy. Biopsy of left fallopian tube and ovary revealed invasive high-grade serous carcinoma of fallopian tube, with involvement of lymphovascular spaces and with surface involvement. Peritoneal washings were negative for malignancy. She was diagnosed with a high-grade serous carcinoma of the fallopian tube after undergoing an endometrial biopsy, multiple imaging tests and finally surgical intervention that yielded the diagnosis. She was started on chemotherapy with carboplatin and paclitaxel. Conclusion: Our aim is to highlight the importance of having PFTC among the differential diagnosis when women present with vaginal bleeding or abdominal pain, as the clinical presentation of PFTC tends to be non-specific, and is often under-diagnosed; reviewing the diagnosis and management, and characterizing the similarities and differences of PFTC with other gynecological malignancies such as ovarian cancer.

1 December 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
JHJasmin Hundal
Jasmin Hundal
KBKatarina Bade
Katarina Bade
EHEmily Hsu
Emily Hsu
JCJyoti Chhabra
Jyoti Chhabra
AMAlvaro Menendez
Alvaro Menendez
PURPOSE: Virtual medicine (VM) use increased during the COVID-19 pandemic as it represented a safe alternative to traditional face-to-face health care delivery. This prospective cross-sectional study aimed to characterize preferences and perceived barriers to VM on the basis of language and specific sociodemographic variables while also identifying particular subpopulations at risk of dissatisfaction regarding VM. METHODS: An institutional review board–approved, 23-item questionnaire was offered in English and Spanish. Examined variables included demographic information, preferences, and perceived barriers regarding VM. Multivariable analysis was performed to determine the association between demographic variables and participants' preferences and perceived barriers. RESULTS: Fewer Hispanic and underserved patients (N = 241) had received oncological care through VM (28.9% v 30.8%) despite comparable preferences and levels of satisfaction regarding the incorporation of VM in health care delivery (21.6% v 25.4%; 68.7% v 82.1%), respectively, with no significant difference by age, level of education, marital status, or Hispanic ethnicity, although Spanish as primary language was statistically significant ( P = .001). Although Hispanic and underserved rely more on social media to receive health information (26.5% v 24.7%), they have more technical barriers. They were up to 2.9 times more likely not to have a phone/iPad/similar or access broadband connectivity. CONCLUSION: Given the shift toward outpatient and home-based care, an aging population, and cultural appropriations, VM excitedly allows the reincorporation of family/caregiver in medical engagement. Hispanic patients are equally interested and satisfied in receiving oncological care through VM, but fewer are currently using it. Barriers are predominantly technical and targetable with appropriate policies to help overcome technological barriers on the basis of language, ethnic, locoregional, and sociodemographic variables.

30 July 2022 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
AJAbhishek Jaiswal
Abhishek Jaiswal
JHJasmin Hundal
Jasmin Hundal
DBDavid Bowers
David Bowers
NGNaga Vaishnavi Gadela
Naga Vaishnavi Gadela
Introduction: Acute respiratory distress syndrome (ARDS) is an uncommon complication of hemophagocytic lymphohistiocytosis (HLH). Non-specific findings that mimic other diseases make timely diagnosis and treatment challenging. We present a rare case of severe ARDS and multiorgan failure from secondary HLH due to peripheral T-cell lymphoma. Case presentation: A middle-aged female presented with dry cough and fever for three days. On presentation, the patient was febrile to 105 degrees F and hypoxic to 88% on room air. Chest X-ray showed bilateral interstitial infiltrates. Laboratory investigations showed lymphopenia and elevated inflammatory markers. The viral panel, including coronavirus disease-2019 (COVID-19), influenza, and respiratory syncytial virus (RSV), was negative. Her respiratory status progressively worsened, requiring invasive mechanical ventilation for ARDS. Despite lung-protective ventilation, prone positioning, and the use of paralytic agents, the patient continued to remain hypoxic, necessitating extracorporeal membrane oxygenation (ECMO) support.The patient was started on antibiotics and high-dose steroid.Thereafter, she developed a leukemoid reaction, and the ferritin level started rising; raising suspicion for lymphophagocytosis. During this time, she also developed acute liver and kidney failure and required multiple vasopressors and renal replacement therapy. Eventually, a diagnosis of mature peripheral T-cell lymphoma was established. Subsequently, her respiratory status and multiorgan failure significantly improved, and ECMO was explanted after 2 weeks. She was started on etoposide and steroid, and eventually discharged after 6 weeks. Discussion: This is the first case describing a successful implementation of ECMO in an adult diagnosed with ARDS secondary to mature peripheral T-cell lymphoma; allowing for recovery of respiratory status, which was compromised during the initial cytokine storm and provided time to establish the diagnosis and initiate appropriate treatment of secondary HLH mature due to peripheral T-cell lymphoma, and in the end, prevented a fatality. We believe that ECMO may be appropriately instituted in rapidly deteriorating patients with an unknown illness refractory to conventional therapy, to allow for end-organ recovery, to reach a diagnosis, and to administer appropriate therapy.